Our community members are treated to special offers, promotions and adverts from us and our partners. You can check out at any time.
Meanwhile, in a separate study, experts from Denmark examined data from Danish health registries to look at data on 27,523 people prescribed both GLP-1 medicines for either obesity or type 2 diabetes and asthma inhalers. They found that GLP-1 use was linked with a 26% fall in the number of asthma exacerbations and a 14% drop in the use of asthma inhaler reliever use.
“In this nationwide cohort of over 27,000 individuals with asthma and also overweight, obesity or type 2 diabetes, use of GLP-1 drugs was associated with significant reductions in exacerbation burden as well as reliever use, exposure to inhaled corticosteroids and pneumonia events, irrespective of whether the drugs were being used to treat obesity or type 2 diabetes,” the authors concluded.
Dr Kjell Erik Julius Hakansson, one of the authors from Copenhagen University Hospital, said: “There is a high chance that the weight loss is a major contributor to these results. A common symptom in both asthma and obesity is shortness of breath, and the presence of excess fatty tissue creates a pro-inflammatory state in the body in general.
